Ongoing Research Report
IN THE NEWS
June 2020: The researchers at the Massachusetts General Hospital announced that they have identified a key mechanism in X chromosome inactivation. The released statement further stated that the phenomenon might hold clues that can lead to treatments for certain rare congenital disorders.
Introduction to Turner Syndrome Drugs
Turner syndrome is a rare genetic disorder condition diagnosed in the female population and occurs when one of the X chromosomes is partially or completely missing. Females diagnosed with this condition are much shorter than the average female and are impotent to conceive due to early loss of ovarian function. A variety of symptoms like the webbed neck, a low hairline at the back of the neck, puffiness or swelling of the hands and feet, skeletal abnormalities, or kidney problems can occur in a large number of patients diagnosed with turner syndrome. The syndrome can be detected early including prenatally, infancy, or in early childhood, and require lifelong medical treatment for several complications that can arise due to syndrome.
Market Size and Forecast
According to the National Library of Medicine in 2017, about 1 in every 2500 new-born girls, around the globe, were diagnosed with turner syndrome, making it one of the primary causes of female-fatal-miscarriages and stillbirths. According to report of National Institute of Health (NIH) U.S., the 45% of patients are affected with classic karyotype and the remaining 55% are affected with mosaic karyotype, a karyotype with abnormally in X chromosomes or may include Y chromosomes or its fragments. Besides, the female population increased from 3.6 billion in 2014 to 3.68 billion in 2016, according to the World Bank. Moreover, an increment of FDA approval for the treatment of the diseases along with the growing biotechnology sector and increasing awareness of women's health is expected to propel the growth of the market.
The turner syndrome drug market is anticipated to show a significant CAGR during the forecast period i.e. 2020-2028. The market is segmented by syndrome type, drug type, therapy type and by end-user. Among these segments, the end-user segment is further segmented to hospitals, homecare, specialty clinics, surgical centers and others, out of which, the segment of hospital is anticipated to hold the leading share in the market on account of availability of turner syndrome drugs used for the patient’s treatment only at the hospital. Global turner syndrome market is a highly disintegrated market and the major players have used various tactics such as joint ventures, partnerships, acquisitions, new product launches, expansion, agreement, and others to increase their mark in this market.
Growth Drivers
Rising Awareness And Concerns For The Health of Women
A rise in patient awareness, prenatal genetic testing, healthcare awareness, and increase in investment in research and developments, and parents awareness and proactiveness towards their child’s health and willingness to seek a physician’s advice at an early stage are some factors that are expected to drive the turner syndrome market over the forecast period.
By Region
On the basis of regional analysis, the turner syndrome drug market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
North America is anticipated to hold the leading shares in the turner syndrome drug market on account of the adoption of new technologies, existence developed economies, rising of healthcare expenditure and massive patient population. Europe holds the second-largest share in the market on account of rising research and development in the healthcare sector, mammoth patient population and growing biotechnology sector.
The turner syndrome drug market is further classified based on region as follows:
IN THE NEWS
June 2020: The researchers at the Massachusetts General Hospital announced that they have identified a key mechanism in X chromosome inactivation. The released statement further stated that the phenomenon might hold clues that can lead to treatments for certain rare congenital disorders.
Introduction to Turner Syndrome Drugs
Turner syndrome is a rare genetic disorder condition diagnosed in the female population and occurs when one of the X chromosomes is partially or completely missing. Females diagnosed with this condition are much shorter than the average female and are impotent to conceive due to early loss of ovarian function. A variety of symptoms like the webbed neck, a low hairline at the back of the neck, puffiness or swelling of the hands and feet, skeletal abnormalities, or kidney problems can occur in a large number of patients diagnosed with turner syndrome. The syndrome can be detected early including prenatally, infancy, or in early childhood, and require lifelong medical treatment for several complications that can arise due to syndrome.
Market Size and Forecast
According to the National Library of Medicine in 2017, about 1 in every 2500 new-born girls, around the globe, were diagnosed with turner syndrome, making it one of the primary causes of female-fatal-miscarriages and stillbirths. According to report of National Institute of Health (NIH) U.S., the 45% of patients are affected with classic karyotype and the remaining 55% are affected with mosaic karyotype, a karyotype with abnormally in X chromosomes or may include Y chromosomes or its fragments. Besides, the female population increased from 3.6 billion in 2014 to 3.68 billion in 2016, according to the World Bank. Moreover, an increment of FDA approval for the treatment of the diseases along with the growing biotechnology sector and increasing awareness of women's health is expected to propel the growth of the market.
The turner syndrome drug market is anticipated to show a significant CAGR during the forecast period i.e. 2020-2028. The market is segmented by syndrome type, drug type, therapy type and by end-user. Among these segments, the end-user segment is further segmented to hospitals, homecare, specialty clinics, surgical centers and others, out of which, the segment of hospital is anticipated to hold the leading share in the market on account of availability of turner syndrome drugs used for the patient’s treatment only at the hospital. Global turner syndrome market is a highly disintegrated market and the major players have used various tactics such as joint ventures, partnerships, acquisitions, new product launches, expansion, agreement, and others to increase their mark in this market.
Growth Drivers
Rising Awareness And Concerns For The Health of Women
A rise in patient awareness, prenatal genetic testing, healthcare awareness, and increase in investment in research and developments, and parents awareness and proactiveness towards their child’s health and willingness to seek a physician’s advice at an early stage are some factors that are expected to drive the turner syndrome market over the forecast period.
By Region
On the basis of regional analysis, the turner syndrome drug market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
North America is anticipated to hold the leading shares in the turner syndrome drug market on account of the adoption of new technologies, existence developed economies, rising of healthcare expenditure and massive patient population. Europe holds the second-largest share in the market on account of rising research and development in the healthcare sector, mammoth patient population and growing biotechnology sector.
The turner syndrome drug market is further classified based on region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
- The Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of the Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Companies Mentioned
- Novartis AG
- Bausch Health
- Johnson & Johnson Services Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Merck & Co.
- Sanofi
- GlaxoSmithKline
- Pfizer
- Other Notable Players
Please note the number of players as well as the addition/deletion can be done in the final deliverable as per the feasibility
